Epicardial adipose tissue and residual cardiovascular risk: a comprehensive case analysis and therapeutic insights with Liraglutide

J Cardiovasc Med (Hagerstown). 2024 Aug 1;25(8):637-641. doi: 10.2459/JCM.0000000000001652. Epub 2024 Jun 20.

Authors

Fulvio Cacciapuoti¹, Ciro Mauro¹, Davide D'Andrea¹, Valentina Capone^{1

2}, Carlo Liguori³, Federico Cacciapuoti⁴

Affiliations

¹ Division of Cardiology, 'A. Cardarelli' Hospital.
² Department of Advanced Medical Sciences, 'Federico II' University.
³ Department of Radiology, 'Ospedale del Mare' Hospital.
⁴ Department of Internal Medicine, 'L. Vanvitelli' University, Naples, Italy.

PMID: 38916237
DOI: 10.2459/JCM.0000000000001652

No abstract available

Publication types

Letter
Case Reports

MeSH terms

Adipose Tissue* / drug effects
Aged
Cardiovascular Diseases / drug therapy
Diabetes Mellitus, Type 2 / complications
Diabetes Mellitus, Type 2 / drug therapy
Epicardial Adipose Tissue
Female
Heart Disease Risk Factors
Humans
Hypoglycemic Agents* / adverse effects
Hypoglycemic Agents* / therapeutic use
Liraglutide* / therapeutic use
Male
Middle Aged
Pericardium* / diagnostic imaging
Pericardium* / drug effects
Treatment Outcome

Substances

Liraglutide
Hypoglycemic Agents